Glaxo Pleads Guilty, Fined $1 Billion in Drug-Marketing Case

GlaxoSmithKline Plc pleaded guilty to illegal promotion of two drugs and failure to provide clinical data on another as part of a $3 billion settlement announced earlier with the U.S., the Justice Department said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.